chevron-down Created with Sketch Beta.
October 13, 2023

Pfizer settles EpiPen Antitrust suit for $50M

Pfizer has agreed to pay $50M to a class of individuals in exchange for being dropped from an antitrust suit that was filed by KPH Healthcare Services against Mylan and Pfizer in February 2020. The suit initially alleged that Pfizer and Mylan engaged in a conspiracy to delay generic competition and forced patients to overpay for epinephrine auto-injector devices used to quickly counteract the effects of severe allergic reactions. In August 2022, a U.S. District Court judge dismissed KPH’s claims against Pfizer, finding that KPH lacked standing. KPH appealed this decision to the U.S. Court of Appeals for the 10th Circuit. While KPH has continued to assert that their claims have merit, they cite the risks of continued litigation in their motion to certify the class and approve the settlement.

The material in all ABA publications is copyrighted and may be reprinted by permission only. Request reprint permission here.